计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B414041-2mg |
2mg |
期货 ![]() |
| |
| B414041-5mg |
5mg |
期货 ![]() |
|
| 英文别名 | BAY-1436032 | US10344004, Test compound Table 3 | SCHEMBL17009632 | BAY 1436032 | s8530 | 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid | MS-29100 | EX-A1606 | CHEMBL4206033 | 3-[2-[ |
|---|---|
| 规格或纯度 | ≥98% |
| 英文名称 | BAY 1436032 |
| 生化机理 | BAY-1436032 是一种高选择性、强效的突变型异柠檬酸脱氢酶 1(mIDH1)口服抑制剂。它在体外对各种 IDH1-R132X 突变体的酶活性具有两位数纳摩尔的选择性泛抑制作用,在患者衍生细胞系和表达不同 IDH1 突变体的工程细胞系中对 2-HG 的释放(纳摩尔范围)具有强效抑制作用。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 异柠檬酸脱氢酶 [NADP] 细胞质抑制剂 |
| 产品介绍 |
Information BAY 1436032 BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1) . It is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displays potent inhibition of 2-HG release (nanomolar range) in patient derived and engineered cell lines expressing different IDH1 mutants. Targets IDH1 (R132H) (Cell-free assay); IDH1 (R132C) (Cell-free assay) 15 nM; 15 nM In vitro BAY 1436032 exhibits an IC50 of 15 nM for mutant IDH1R132H protein and virtually no effect on wild-type IDH1 and the structurally related IDH2 proteins with IC50 of 20 and >100 µM, respectively. BAY 1436032 not only reduces 2-HG levels in cells with the IDH1R132H or the IDH1R132C mutations, but also in those with the R132G, R132S or R132L mutations with equal efficiency. There is no inhibition of IDH2 R172M. BAY 1436032 reduces proliferation and induces differentiation in primary glioma cultures. BAY 1436032 reveals low metabolic clearance (CL) in vitro in rat hepatocytes and mice liver microsomes. In vivo The pharmacokinetic properties of BAY 1436032 allow for oral administration. In vivo pharmacokinetics (PK) in rats shows low CL and high oral bioavailability. Oral administration of BAY 1436032 confers a survival benefit to mice transplanted with IDH1 mutant tumors. BAY 1436032 induces differentiation in intracranial xenografts. Cell Research(from reference) Cell lines:NCH551b patient-derived glioma cell lines Concentrations:500 nM and 2.5 µM Incubation Time:1 day |
| 纯度 | ≥98% |
| ALogP | 7.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid |
| INCHI | 1S/C26H30F3N3O3/c1-16-12-19(15-25(2,3)14-16)32-22-10-4-17(5-11-23(33)34)13-21(22)31-24(32)30-18-6-8-20(9-7-18)35-26(27,28)29/h4,6-10,13,16,19H,5,11-12,14-15H2,1-3H3,(H,30,31)(H,33,34)/t16-,19+/m0/s1 |
| InChi Key | RNMAUIMMNAHKQR-QFBILLFUSA-N |
| Smiles | CC1CC(CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F |
| Isomeric SMILES | C[C@H]1C[C@H](CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F |
| 分子量 | 489.53 |
| Reaxy-Rn | 41384858 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=41384858&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 98 mg/mL (200.19 mM); Ethanol: 98 mg/mL (200.19 mM); Water: Insoluble; |
|---|---|
| 分子量 | 489.500 g/mol |
| XLogP3 | 7.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 489.224 Da |
| 单同位素质量Monoisotopic Mass | 489.224 Da |
| 拓扑极表面积Topological Polar Surface Area | 76.400 Ų |
| 重原子数Heavy Atom Count | 35 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 726.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |